Pure Global
ISRCTN17422256

MyDiabetes IQ - AI-powered decision support tool for diabetes clinicians

MyDiabetes IQ - safety and efficacy testing of a diagnosis and precision medicine tool for diabetes management
MyWay Digital Health Ltd·ISRCTN Registry·combination product
Study focus
Disease/Condition
Diabetes mellitus
Study type
Interventional
Intervention type
combination product
Sponsor & location
Primary sponsor
MyWay Digital Health Ltd
Funder
National Institute for Health Research
Location
United Kingdom
Timeline & enrollment
Phase
N/A
Start date
Aug 02, 2021
End date
Jul 28, 2023
Enrollment
19 participants
Summary

Primary hypothesis: MyDiabetes IQ (MDIQ) is safe within both simulated and real-world clinical environments. Secondary hypotheses: MDIQ is usable; MDIQ is useful; MDIQ has an impact on clinician prescribing and diagnosing; MDIQ has an impact on patient metabolic outcomes.

ICD-10 classifications
Diabetes mellitusUnspecified diabetes mellitusOther specified diabetes mellitusUnspecified diabetes mellitus without complicationsUnspecified diabetes mellitus with unspecified complications
Data source
Registry
ISRCTN Registry
Trial ID
ISRCTN17422256
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for ISRCTN17422256 through Pure Global AI's free database. This phase not specified trial is sponsored by MyWay Digital Health Ltd and is currently status unknown. The study focuses on Diabetes mellitus. Target enrollment is 19 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ISRCTN Registry data, helping medical device and pharmaceutical companies navigate clinical research efficiently.